ReviewInternational journal of oncology2024
Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review).
Review in International journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Platelet-to-lymphocyte ratio and systemic inflammation response index are the optimal combination for risk stratification in patients with nasopharyngeal carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Unveiling the multifaceted roles of BCL3: biological functions and disease implications.Apoptosis : an international journal on programmed cell death · 2026Review
- Understanding the immunomodulatory mechanisms for natural products that overcome tumor chemoresistance to platinum-based cancer drugs and other treatments.Frontiers in pharmacology · 2026Review
- Therapy-induced mRNA, rRNA and tRNA methylation alterations confer tolerance phenotype in tumor cells: mechanism and implications.International journal of biological sciences · 2026Review
- Integrative machine learning identifies lactylation-related gene signature prognostic for chemotherapeutic efficacy in colorectal carcinoma.Discover oncology · 2025Article
- Deciphering macrophage heterogeneity and factors driving M2 polarization in lung adenocarcinoma through single-cell RNA sequencing.Apoptosis : an international journal on programmed cell death · 2025Article
- DNA, RNA, and histone methylation regulation enzymes and their crosstalk in colorectal carcinogenesis and progression: a review of molecular mechanisms, clinical implications, and future perspectives.Cellular & molecular biology letters · 2025Review
- Salvigenin: a natural ally against nasopharyngeal carcinoma's malignant phenotypes and immune evasion.Journal of molecular histology · 2025Article
- The mMolecular biomedicine · 2025Review
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- Dissecting the METTL3/STC2 axis in colorectal cancer: implications for drug resistance and metastasis.Cell biology and toxicology · 2025Article
- PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma.Journal of nanobiotechnology · 2025Article
- The impact of the ATP-binding cassette (ABC) transporter family on multidrug resistance in head and neck tumors.Molecular biology reports · 2025Review
- The impact of the ATP-binding cassette (ABC) transporter family on multidrug resistance in head and neck tumors.Molecular biology reports · 2025Review
- A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma.Discover oncology · 2025Article
- Small-molecule and peptide inhibitors of m6A regulators.Frontiers in oncology · 2025Review
- METTL1 mediates PKM m7G modification to regulate CD155 expression and promote immune evasion in colorectal cancer.Journal of translational medicine · 2024Article
- METTL protein family: focusing on the occurrence, progression and treatment of cancer.Biomarker research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA methylation modifications are closely linked to tumor development, migration, invasion and responses to various therapies. Recent studies have shown notable advancements regarding the roles of RNA methylation in tumor immunotherapy, the tumor microenvironment and metabolic reprogramming. However, research on the association between tumor chemoresistance and N6‑methyladenosine (m6A) methyltransferases in specific cancer types is still scarce. Colorectal cancer (CRC) is among the most common gastrointestinal cancers worldwide. Conventional chemotherapy remains the predominant treatment modality for CRC and chemotherapy resistance is the primary cause of treatment failure. The expression levels of m6A methyltransferases, including methyltransferase‑like 3 (METTL3), METTL14 and METTL16, in CRC tissue samples are associated with patients' clinical outcomes and chemotherapy efficacy. Natural pharmaceutical ingredients, such as quercetin, have the potential to act as METTL3 inhibitors to combat chemotherapy resistance in patients with CRC. The present review discussed the various roles of different types of key RNA methylation enzymes in the development of CRC, focusing on the mechanisms associated with chemotherapy resistance. The progress in the development of certain inhibitors is also listed. The potential of using natural remedies to develop antitumor medications that target m6A methylation is also outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.